Low-Frequency Contralesional rTMS Shows Promise for Post-Stroke Neurogenic Overactive Bladder

For stroke survivors battling neurogenic overactive bladder—a condition marked by involuntary urine leakage and pelvic floor dysfunction—there may soon be a noninvasive, drug-free solution on the horizon. A landmark study published in Neurorehabilitation & Neural Repair demonstrates that low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the contralesional hemisphere can significantly improve symptoms while maintaining an exceptional safety profile. But what does this mean for patients, clinicians and the broader stroke rehabilitation ecosystem? The answer lies in understanding the trial’s rigorous design, its biological plausibility, and the urgent need for specialized care pathways to bridge research to practice.

Key Clinical Takeaways:

• Low-frequency rTMS applied to the contralesional motor cortex reduces neurogenic overactive bladder symptoms in stroke survivors by modulating cortical excitability, with effects persisting for at least 4 weeks post-treatment.
• The intervention carries minimal adverse events, primarily mild scalp discomfort or transient headaches, making it suitable for subacute to chronic stroke populations.
• Current protocols require further validation in Phase III trials before FDA clearance, but early data suggest it could become a first-line adjunct to physical therapy for this debilitating complication.

Neurogenic Overactive Bladder After Stroke: A Persistent Clinical Gap

Stroke remains the leading cause of long-term disability worldwide, with neurogenic overactive bladder (OAB) affecting up to 60% of survivors in the first year post-event, according to the American Stroke Association’s 2022 consensus guidelines. Traditional management relies on anticholinergic medications—often poorly tolerated—or invasive sacral neuromodulation, neither of which addresses the underlying cortical dysfunction driving bladder dysfunction. Enter low-frequency rTMS, a noninvasive neuromodulation technique that has shown promise in restoring motor and cognitive function post-stroke. The new study published in Neurorehabilitation & Neural Repair builds on this foundation by targeting the contralesional hemisphere (the side opposite the stroke lesion), a strategy designed to disrupt maladaptive interhemispheric inhibition and restore bladder control circuits.

“The contralesional approach is theoretically grounded in the concept of transcallosal inhibition, where the unaffected hemisphere suppresses recovery in the damaged hemisphere. By applying inhibitory low-frequency rTMS to the contralesional motor cortex, we effectively ‘release the brake’ on the lesioned side, allowing for functional reorganization.”

Trial Design and Efficacy: What the Data Reveals

The study—a double-blind, sham-controlled, randomized trial conducted across three rehabilitation centers in South Korea—enrolled 82 subacute to chronic stroke survivors (mean age 58 years. 42% female) with neurogenic OAB confirmed via urodynamic testing. Participants received either 1 Hz rTMS (active treatment) or sham stimulation over the contralesional M1 (primary motor cortex) for 20 minutes daily, 5 days per week, for 4 weeks. Primary outcomes measured changes in the International Consultation on Incontinence Questionnaire-Overactive Bladder (ICIQ-OAB) score, while secondary endpoints included bladder diary metrics, quality of life (SF-36), and cortical excitability via transcranial magnetic stimulation mapping.

Source: Neurorehabilitation & Neural Repair (2026). Data extracted from the full-text study protocol.

Biological Mechanism: How rTMS Rewires the Bladder Control Network

The contralesional rTMS protocol leverages two key neurophysiological principles:

1. Disruption of Transcallosal Inhibition: Stroke-induced hyperactivity in the contralesional hemisphere suppresses recovery in the lesioned hemisphere. Low-frequency rTMS (1 Hz) induces long-term depression (LTD)-like effects, reducing excitatory drive from the contralesional motor cortex to the lesioned side, thereby facilitating cortical reorganization.
2. Modulation of the Pontine Micturition Center: The bladder control network involves a cortico-pontine-spinal loop. By normalizing cortical excitability, rTMS may restore inhibitory control over the pontine micturition center, reducing detrusor overactivity—a hallmark of neurogenic OAB.

Supporting this mechanism, the study reported a 28% reduction in cortical silent period duration in the lesioned hemisphere post-treatment, correlating with clinical improvements (r=0.62, p<0.001).

Funding Transparency and Regulatory Pathway

The trial was funded by the National Research Foundation of Korea (NRF) under Grant No. NRF-2023R1A2C2003564, with additional support from the Seoul National University Hospital Clinical Research Institute. Disclosure of funding sources is critical: public grants ensure independence from pharmaceutical bias, though the study’s authors note a potential conflict of interest with MagVenture, the manufacturer of the rTMS device used, which provided equipment in-kind.

With Phase II data now published, the next step is FDA Investigational Device Exemption (IDE) submission, targeting a Breakthrough Device designation given the unmet need. The FDA’s 2023 guidance emphasizes patient access for high-impact neuromodulation therapies, positioning rTMS as a prime candidate.

Clinical Triage: Who Should Offer This Therapy—and Where?

The study’s findings underscore an urgent need for stroke rehabilitation centers to integrate rTMS into their neurogenic bladder protocols. However, not all clinics are equipped to deliver this therapy safely. Key considerations for providers:

• Specialized Training: rTMS requires certification in neuromodulation techniques. Clinics should partner with board-certified neurologists or physiatrists trained in rTMS protocols.
• Device Compatibility: The study used a MagPro X100 stimulator, but not all devices are equivalent. Patients should verify their clinic’s equipment meets FDA’s safety standards.
• Multidisciplinary Teams: Optimal outcomes require collaboration between urogynecologists, physical therapists, and rTMS specialists. For example, McLeod Health’s Loris, SC, clinic offers integrated stroke rehabilitation with neuromodulation capabilities.

“Neurogenic OAB is often overlooked in stroke recovery plans, yet it profoundly impacts quality of life. RTMS offers a noninvasive bridge while patients await surgical options. The challenge now is scaling access—this isn’t just a medical breakthrough, it’s a healthcare infrastructure challenge.”

The Future: Toward a Standard of Care for Neurogenic OAB

While the Phase II results are promising, several questions remain:

• Will the effects persist beyond 4 weeks? Longitudinal studies are needed to assess durability.
• How does rTMS compare to sacral neuromodulation in terms of cost and efficacy? A head-to-head trial is warranted.
• Can this protocol be adapted for other stroke-related complications, such as spasticity or aphasia?

For now, the data suggests that low-frequency contralesional rTMS could become a first-line adjunctive therapy for neurogenic OAB, particularly for patients who fail conservative measures. The next critical phase is real-world implementation. Clinics should begin preparing by:

• Establishing rTMS certification programs for rehabilitation staff.
• Collaborating with healthcare compliance attorneys to navigate FDA IDE requirements.
• Integrating rTMS into stroke rehabilitation pathways as a standardized offering.

The window for adoption is now. As Dr. Cho notes, “The science is ready—now we need the systems to deliver it.”

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.